HMP Global

Oncology Learning Network

Health EN ↓ 191 episodes

Podcast by HMP Global

Be sure to visit the podcast's website and support the creator: soundcloud.com

Author

HMP Global

Category

Health

Podcast website

soundcloud.com

Latest episode

Nov 4, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Artificial Intelligence Advances Lymphoma Diagnosis, Biomarker Identification, and Precision Treatment 04.11.2026
Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice 13.10.2026

In this podcast, David Portnoy, MD, a medical oncologist at the West Cancer Center and Research Institute in Memphis, Tennessee, discusses how he approaches treatment selection for patients with advanced cutaneous squamous cell carcinoma in a largely rural region. Topics include the three FDA-approved checkpoint inhibitors, patient factors such as age, comorbidities, and ability to tolerate advers...

Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice 29.09.2026

In this expert discussion, Bahar Dasgeb, MD, shares a patient-centered approach to treatment selection for advanced cutaneous squamous cell carcinoma, including how disease characteristics, autoimmune and inflammatory conditions, and treatment tolerability can inform decisions about systemic therapy. She also discusses her clinical experience with cosibelimab, including its potential role in patie...

Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice 21.09.2026

In this podcast, Omid Hamid, MD, discusses how clinicians can individualize treatment selection for patients with advanced cutaneous squamous cell carcinoma based on factors such as age, performance status, comorbidities, and the risk of immune-related toxicities. Through a real-world patient case, he explores considerations surrounding the use of cosibelimab, its PD-L1–targeting mechanism and ant...

Preparing for Biomarker-Directed Care in epNEC: What Pathologists Need to Know Now 26.08.2026

This podcast features Dr David Klimstra discussing how pathologists can prepare for biomarker-directed care in extrapulmonary neuroendocrine carcinoma (epNEC). Key topics include accurate NEC classification before delta-like ligand 3 (DLL3) assessment, tissue stewardship, timing and location of immunohistochemistry testing, evolving scoring thresholds, and the importance of close pathology-oncolog...

Artificial Intelligence for Skin Cancer Diagnosis 04.08.2026

Luc Thomas, MD, PhD, discusses findings from a real-world study comparing artificial intelligence models with clinicians for skin cancer diagnosis, highlighting the strengths and limitations of artificial intelligence and reinforcing the continued importance of physician expertise in dermoscopy and melanoma detection.

Testing Matters: Practical Approaches to Biomarker Evaluation in NSCLC 14.07.2026

Dr Jamie Chaft reviews the importance of early tissue stewardship in NSCLC, including how biopsy planning, tissue adequacy, and coordination across the care team can influence biomarker testing and treatment planning. The discussion emphasizes practical strategies to support current and future molecular testing needs. 

Connecting the Dots: How MET Fits Into Comprehensive Molecular Profiling 14.07.2026

Dr Jamie Chaft reviews the biological and clinical differences among MET biomarkers in NSCLC, emphasizing the importance of matching the specific biomarker question to the appropriate assay. The discussion covers NGS, IHC, and FISH, as well as specimen availability, prior therapy exposure, and the evolving clinical context. 

Real-World Decision Points in Biomarker-Driven NSCLC Management 14.07.2026

Dr Jamie Chaft discusses how longitudinal biomarker assessment can support treatment planning, resistance evaluation, and rebiopsy decision-making in NSCLC. Key topics include disease progression, tissue limitations, prior assay results, multidisciplinary collaboration, and individualized testing strategies. 

Beyond FVC: What FIBRONEER-ILD Means for Outcomes, Patients, and Access in PPF 14.07.2026

In this expert commentary, Toby Maher, MD, PhD, discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the potential implications of the longer-term FIBRONEER-ILD trial findings. He explores how nerandomilast may address key unmet needs in PPF, with a focus on disease progression, clinically meaningful outcomes, treatment sequencing, and the broader impact on patien...

Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma 08.07.2026

Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell lymphoma, supporting this regimen as a potential new frontline standard of care regardless of molecular subtype.

Closing the Gap Between CAR T–Cell Therapy Recognition and Referral in Multiple Myeloma 22.06.2026

Samantha Shenoy, NP, and Caitlin Costello, MD, discuss how oncology care teams can close the gap between recognizing a patient with multiple myeloma as a potential CAR T-cell therapy candidate and getting that patient to evaluation. The episode highlights referral readiness, documentation, shared-care coordination, and common barriers that can delay timely evaluation.

When to Raise the Question of CAR T–Cell Therapy in Multiple Myeloma 22.06.2026

Samantha Shenoy, NP, and Caitlin Costello, MD, discuss how risk stratification, early relapse patterns, and changes in disease trajectory can help oncology care teams recognize when a patient with multiple myeloma may warrant consideration for cellular therapy, including CAR T-cell therapy. The episode highlights the role of nurses and advanced practice providers in identifying clinical shifts and...

Olverembatinib Plus Blinatumomab Produces Deep Responses in Ph+ Acute Lymphoblastic Leukemia 05.06.2026

Elias Jabbour, MD, MD Anderson Cancer Center, Houston, Texas, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

How Are We Detecting Residual Disease in Lymphoma Today? 04.06.2026

This podcast reviews current and emerging approaches to residual disease detection in diffuse large B-cell lymphoma, emphasizing the role of PET-CT imaging in assessing treatment response and predicting relapse risk. Dr. David Russler-Germain discusses the limitations of PET-CT and highlights growing evidence that ctDNA-based MRD testing may provide more accurate prognostic information and improve...

How Are We Detecting Residual Disease in Lymphoma Today? 04.06.2026

This podcast explores the principles and clinical applications of circulating ctDNA-based MRD testing in diffuse large B-cell lymphoma, including how personalized sequencing assays can detect microscopic residual disease with greater sensitivity than imaging. Dr. David Russler-Germain discusses the growing evidence supporting ctDNA MRD testing for prognostication and treatment monitoring, while al...

How is ctDNA MRD Testing Used in Lymphoma Care? 04.06.2026

This podcast examines the clinical utility of ctDNA-based MRD testing in diffuse large B-cell lymphoma, focusing on its role in post-treatment risk stratification, relapse detection, and treatment decision-making. Dr. David Russler-Germain reviews evidence showing that ctDNA MRD testing provides stronger prognostic value and earlier detection of recurrence than PET-CT imaging, supporting its growi...

Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG) 30.12.2025

Guest host Cassie Kline, MD, MAS, presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating clinically meaningful endpoints into future trials, as they may better reflect real-world patient benefit than radiographic criteria alone. ...

Navigating The Complexity of Melanoma Care: Part 1 21.05.2025
Navigating The Complexity of Melanoma Care: Part 2 21.05.2025
Navigating The Complexity of Melanoma Care: Part 3 21.05.2025
Navigating The Complexity of Melanoma Care: Part 4 21.05.2025
Navigating The Complexity of Melanoma Care: Part 5 21.05.2025
Navigating The Complexity of Melanoma Care: Part 6 21.05.2025
Community Education Program Improves Patient Education and Cancer Screening Rates 14.05.2025

Listen to the Oncology Learning Network podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.